Acute pancreatitis with saw palmetto use: A case report

被引:9
作者
Bruminhent J. [1 ]
Carrera P. [1 ]
Li Z. [1 ]
Amankona R. [1 ]
Roberts I.M. [1 ]
机构
[1] University of Connecticut School of Medicine, Department of Internal Medicine, St Vincent's Medical Center, Bridgeport, CT 06606
关键词
Pancreatitis; Acute Pancreatitis; Benign Prostatic Hyperplasia; Lansoprazole; Finasteride;
D O I
10.1186/1752-1947-5-414
中图分类号
学科分类号
摘要
Introduction. Saw palmetto is a phytotherapeutic agent commercially marketed for the treatment of benign prostatic hyperplasia. Evidence suggests that saw palmetto is a safe product, and mild gastrointestinal adverse effects have been reported with its use. We report a case of acute pancreatitis, possibly secondary to the use of saw palmetto. Case presentation. A 61-year-old Caucasian man with a history of benign prostatic hyperplasia and gastroesophageal reflux disease developed epigastric pain associated with nausea 36 hours prior to presentation. He denied drinking alcohol prior to the development of his symptoms. His home medications included saw palmetto, lansoprazole and multivitamins. Laboratory results revealed elevated lipase and amylase levels. An abdominal ultrasound demonstrated a nondilated common bile duct, without choledocholithiasis. Computed tomography of his abdomen showed the pancreatic tail with peripancreatic inflammatory changes, consistent with acute pancreatitis. Our patient's condition improved with intravenous fluids and pain management. On the fourth day of hospitalization his pancreatic enzymes were within normal limits: he was discharged home and advised to avoid taking saw palmetto. Conclusion: It is our opinion that a relationship between saw palmetto and the onset of acute pancreatitis is plausible, and prescribers and users of saw palmetto should be alert to the possibility of such adverse reactions. © 2011 Bruminhent et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 30 条
[1]  
Germplasm Resources Information Network. GRIN Taxonomy for Plants - Serenoa Repens (W. Bartram) Small
[2]  
George W., Tanner G., Mullahey J., Maehr D., Saw-palmetto: An Ecologically and Economically Important Native Palm. WEC-109, (1999)
[3]  
Ravenna L., Di Silverio F., Russo M.A., Salvatori L., Morgante E., Morrone S., Cardillo M.R., Russo A., Frati L., Gulino A., Petrangeli E., Effects of the lipidosterolic extract of Serenoa repens (Permixon®) on human prostatic cell lines, Prostate, 29, 4, pp. 219-230, (1996)
[4]  
Carilla E., Briley M., Fauran F., Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate, Journal of Steroid Biochemistry, 20, 1, pp. 521-523, (1984)
[5]  
Bayne C.W., Donnelly F., Ross M., Habib F.K., Serenoa repens (Permixon®): A 5α-reductase types I and II inhibitor - New evidence in a coculture model of BPH, Prostate, 40, 4, pp. 232-241, (1999)
[6]  
Goldmann W.H., Sharma A.L., Currier S.J., Johnston P.D., Rana A., Pal Sharma C., Saw Palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells, Cell Biology International, 25, 11, pp. 1117-1124, (2001)
[7]  
Wilt T.J., Ishani A., Stark G., MacDonald R., Lau J., Mulrow C., Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review, Journal of the American Medical Association, 280, 18, pp. 1604-1609, (1998)
[8]  
Dimitrakov J.D., Saw palmetto for benign prostatic hyperplasia, N Engl J Med, 354, 18, pp. 1950-1951, (2006)
[9]  
Tacklind J., MacDonald R., Rutks I., Wilt T.J., Serenoa repens for benign prostatic hyperplasia, Cochrane Database Syst Rev, 15, 2, (2009)
[10]  
Agbabiaka T.B., Pittler M.H., Wider B., Ernst E., Serenoa repens (Saw palmetto): A systematic review of adverse events, Drug Saf, 32, 8, pp. 637-647, (2009)